Stock ACAD ACADIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-03 pm EDT 		5-day change 1st Jan Change
17.05 USD -0.18% Intraday chart for ACADIA Pharmaceuticals Inc. +2.03% -45.54%
Apr. 30 UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating MT
Apr. 23 Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
BU
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
BU
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
BU
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
BU
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
BU
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BU
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 15, 2024
AQ
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
PR
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
PR
Acadia Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference on March 6, 2024
AQ
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
BU
Acadia: Q4 Earnings Snapshot
AQ
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
BU
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACAD Stock
  4. News ACADIA Pharmaceuticals Inc.
  5. Press Releases